LR Health & Beauty Further Expands its Expertise in the Health Sector – Launch of New Health Brand LR Lifetakt
LR Health & Beauty, with headquarters in Ahlen (Germany), has over 20 years of expertise in the production of food supplements. Focussing even more strongly on the needs of consumers, the network marketing company has invested significantly in the healthcare sector and designed a modern health management system surrounding the new health brand LR Lifetakt. The brand will be introduced in the countries where LR is active gradually.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180103005488/en/
An important component of the LR Lifetakt overall solutions: the Aloe Vera Drinking Gels. Photo: LR Health & Beauty
The health segment is one of the main growth drivers at LR. “The market for innovative healthcare concepts as a whole has grown extremely rapidly throughout Europe. More and more people are taking their health into their own hands. With our new strong LR Lifetakt brand, we can be a competent partner for these people – true to our motto ‘More quality for your life’”, says Dr. Thomas Stoffmehl, CEO of LR Health & Beauty.
LR Lifetakt bundles high-quality food supplements and meal replacement products, which were put together by experts to form six overall solutions and thus meet the most important demands on the healthcare market: nutrient supply for every day, vitality at every age, weight management, enhanced performance, seasonal support and unrestricted mobility. LR follows a holistic approach. The solutions are based on a newly developed three-pillar system: a basic solution, individual product supplements and additional expert tips on nutrition and lifestyle. Additionally the tailor-made sales concept supports the sales partners as best as possible in their customer meetings and thus in successful business development.
LR attaches great importance to the quality of its products. In Ahlen, the company recently built the most modern production site for Aloe vera products in Europe. From February 2018, LR Aloe Vera Drinking Gels will be produced there. These are an important component of the LR Lifetakt overall solutions. "Aloe vera products are one of the core competencies of LR. Since 2002, we have sold more than 55 million litres of Aloe Vera Drinking Gels. With the production site, we are reinforcing our claim 'Made in Germany'", says Dr. Thomas Stoffmehl.
LR Health & Beauty
Under the motto "More quality for your life", the LR Group with headquarters in Ahlen/Westphalia produces and markets more than 600 health and beauty products in 28 countries. This includes body care and cosmetic products, perfumes and dietary supplements. In the fragrance segment, the company, which was founded in 1985, cooperates with celebrities such as Bruce Willis, Karolina Kurkova and Guido Maria Kretschmer. With more than 1,200 employees and thousands of registered sales partners and customers, LR is one of Europe’s leading direct sales enterprises. LR's strong market position is based above all on a high-quality product range and an attractive bonus and training plan which is unsurpassed in the industry. In 2009, LR established the LR Global Kids Fund which provides efficient and unbureaucratic support for deprived children and their families in many different countries around the world in cooperation with local institutions.
LR Health & Beauty
Head of PR / Public Affairs
Tel: +49 2382 70 60 114
impact Agentur für Kommunikation GmbH
Tel. + 49 69 955264-33
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
H.I.G. Capital Invests in Prime Office Building in Milan25.4.2018 15:21 | Tiedote
H.I.G. Capital, LLC ("H.I.G."), a leading global private equity investment firm with over €20 billion of equity capital under management, announced today that one of its affiliates has recently completed an investment of an 8,600 sqm trophy office building in the historical centre of Milan. The flagship building will undergo an extensive renovation, benefiting from the strong occupier market which is attracting the interest of major international tenants especially in the financial sector. Terms were not disclosed. H.I.G. continues to add to its sizeable holdings of real estate assets across Europe, consisting of both equity as well as debt investments, with a particular focus on its target market of value-added small/midcap opportunities. Riccardo Dallolio, Managing Director and Head of H.I.G. Europe Realty Partners in London, commented: “Our focus in Italy is on high quality assets with the potential of becoming highly liquid institutional product as the result of the envisaged value
Westinghouse AP1000® Plant to Load Fuel25.4.2018 15:14 | Tiedote
Westinghouse Electric Company, China State Nuclear Power Technology Corporation (SNPTC) and CNNC Sanmen Nuclear Power Company Limited (SMNPC) announced today that the world’s first unit of AP1000 nuclear power plant located in Sanmen, Zhejiang Province, China, has received the fuel load permit from China’s National Nuclear Safety Administration (NNSA) and has commenced initial fuel loading. “Today we have reached a tremendous milestone for Westinghouse and our AP1000 plant technology,” said José Emeterio Gutiérrez, Westinghouse president and chief executive officer. “This is the next major step in delivering the world’s first AP1000 plant to our customer and demonstrating the benefits of our advanced passive safety technology to the world.” Sanmen Unit 1 has successfully completed all the necessary functional tests as well as technical, safety and Chinese regulatory reviews. The fuel load process will be followed by initial criticality, initial synchronization to the electrical grid, a
Elliott Advisors (UK) Limited Statement on Whitbread25.4.2018 15:03 | Tiedote
Elliott Advisors (UK) Limited (“Elliott”) is pleased that Whitbread has announced a demerger and has committed to doing so “as fast as practical”. In Elliott’s view this should be achieved within six months. About Elliott Elliott Management Corporation manages two multi-strategy funds which combined have approximately $35 billion of assets under management. Its flagship fund, Elliott Associates, L.P., was founded in 1977, making it one of the oldest funds of its kind under continuous management. The Elliott funds’ investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, and employees of the firm. Elliott Advisors (UK) Limited is an affiliate of Elliott Management Corporation. View source version on businesswire.com: https://www.businesswire.com/news/home/20180425005814/en/ Contact information Media Contacts Elliott Advisors (UK) Limited Sarah Rajani CFA Director of Communications Elliott Advisors (UK) Limited +44 (0) 20 3009 1818 srajani@elliott
Incognito Launches Digital Home Experience Solution25.4.2018 15:00 | Tiedote
Incognito Software Systems, a global provider of device and service management solutions for digital service providers, today introduced the Digital Home Experience Solution. The new offering enhances the existing Incognito Auto Configuration Server with improved digital channels, and analytics to address service quality challenges associated with complex, multi-device home WiFi networks. In production with a Tier 1 service provider, the solution is accelerating technical problem resolution, reducing operational costs with fewer truck rolls, while improving customer satisfaction. “Digital transformation in the home network is accelerating, as service providers look to eliminate friction points such as how to automate the resolution of service quality issues,” said Anil Rao, Principal Analyst, Analysys Mason. “It is in this context that Incognito’s new Digital Home Experience Solution is relevant. Communication service providers are investing in such solutions to boost customer satisfac
Boehringer Ingelheim R&D Pushes to Transcend Disease Boundaries25.4.2018 14:30 | Tiedote
Family-owned pharmaceutical company Boehringer Ingelheim today presented its latest pipeline updates at a Research & Development press conference entitled ‘Transcending Disease Boundaries’, at its global headquarters in Ingelheim, Germany. The company’s R&D strategy and current pipeline has the potential to deliver 15 new medicines for approval by 2025 (probability adjusted). With a high percentage of first-in-class and breakthrough potential drug candidates, Boehringer Ingelheim continues the successful implementation of its R&D strategy. Boehringer Ingelheim is committing more than €20 billion to Research & Development for human pharmaceuticals by 2025. In the past four years, the company received 14 regulatory approvals in several new indications, including four new molecular entities and four breakthrough designations by the US Food and Drug Administration. “The most ambitious goal for researchers is to achieve a medical breakthrough for patients from our over 80 clinical and pre-c
Corvidia Therapeutics Secures $60 Million in Series B Funding to Accelerate Clinical Work25.4.2018 14:00 | Tiedote
Corvidia Therapeutics Inc., a leading clinical stage biotechnology company, today announced the close of a $60 million USD Series B funding round. The financing will accelerate growth of Corvidia’s ongoing clinical programs, expand scientific and market access capabilities and explore new treatment areas. Venrock led the Series B financing and was joined by five additional new investors: Andera (formerly Edmond de Rothschild), Cormorant Asset Management, HBM Healthcare Investments, Fresenius Medical Care Ventures GmbH and Venrock Healthcare Capital Partners (VHCP). Series A investors Apple Tree Partners, MedImmune, the global biologics Research and Development arm of AstraZeneca, and Sofinnova Partners, the founding seed investor, also participated in this round. “We are extremely pleased to have reached such an important milestone in Corvidia’s advancement as a biotechnology company,” said Marc de Garidel, Chief Executive Officer of Corvidia Therapeutics Inc. “This funding is critical
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme